News

Arvelle Therapeutics is involved in the development of advanced solutions to treat patients suffering from central nervous system (CNS) disorders. The company is currently engaged in the development

The approval has been given following the recommendation of its Subject Expert Committee (SEC). Additionally, recommendation has been made for the approval of the Phase III clinical trial

Under the terms of the proposed agreement, the company will commence distribution of the vaccine in the second quarter of 2021. The Moderna COVID-19 vaccine has not been

Expected to improve competition and access to more affordable medicines, the approval has been given to the first generic of glucagon for injection USP, 1 mg/vial packaged in

UB-612 is said to be the first multitope, synthetic peptide-based Covid-19 vaccine candidate. Under the terms of the deal, Aurobindo Pharma will leverage its existing development, commercial and

Anle138b is a disease-modifying treatment option for synucleinopathies, such as Multiple System Atrophy (MSA) and PD. The short-term Phase 1b study with PD patients will be conducted by

Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase designed to be used as subcutaneous (SC) injection. Phesgo integrates the same monoclonal antibodies as

Merck acquired MK-7110 through the acquisition of OncoImmune, a privately held, clinical-stage biopharmaceutical company. “Building upon the promising clinical findings to date for MK-7110, Merck is pleased to

With the latest deal, the companies now will deliver up to 200 million doses to the US. Both firms plan to supply the full 200 million doses to